157 related articles for article (PubMed ID: 37566295)
1. Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
Ding WY; Fawzy AM; Romiti GF; Proietti M; Pastori D; Huisman MV; Lip GYH;
J Thromb Thrombolysis; 2024 Jan; 57(1):39-49. PubMed ID: 37566295
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA-AF Registry.
Ding WY; Lane DA; Gupta D; Huisman MV; Lip GYH;
J Am Heart Assoc; 2022 Aug; 11(15):e026410. PubMed ID: 35876418
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study.
Sanmartín Fernández M; Anguita Sánchez M; Arribas F; Barón-Esquivias G; Barrios V; Cosin-Sales J; Esteve-Pastor MA; Freixa-Pamias R; Lekuona I; Pérez-Cabeza AI; Ureña I; Vázquez Rodríguez JM; Rafols Priu C; Marin F
Cardiol J; 2022; 29(4):601-609. PubMed ID: 35621092
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation.
Rivera-Caravaca JM; Marín F; Esteve-Pastor MA; Raña-Míguez P; Anguita M; Muñiz J; Cequier Á; Bertomeu-Martínez V; Valdés M; Vicente V; Lip GYH; Roldán V
Am J Cardiol; 2017 Dec; 120(12):2176-2181. PubMed ID: 29111209
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score.
Pastori D; Farcomeni A; Poli D; Antonucci E; Angelico F; Del Ben M; Cangemi R; Tanzilli G; Lip GY; Pignatelli P; Violi F
Intern Emerg Med; 2016 Mar; 11(2):199-204. PubMed ID: 26471883
[TBL] [Abstract][Full Text] [Related]
6. Adverse cardiovascular outcomes in atrial fibrillation: Validation of the new 2MACE risk score.
Polovina M; Đikić D; Vlajković A; Vilotijević M; Milinković I; Ašanin M; Ostojić M; Coats AJS; Seferović PM
Int J Cardiol; 2017 Dec; 249():191-197. PubMed ID: 28986061
[TBL] [Abstract][Full Text] [Related]
7. Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry.
Ding WY; Calvert P; Gupta D; Huisman MV; Lip GYH;
Clin Res Cardiol; 2022 Sep; 111(9):1057-1068. PubMed ID: 35488127
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry.
Lip GYH; Kotalczyk A; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Marler S; Gurusamy VK; Huisman MV;
Clin Res Cardiol; 2022 May; 111(5):560-573. PubMed ID: 35294625
[TBL] [Abstract][Full Text] [Related]
9. Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation.
Rivera-Caravaca JM; Teruel-Montoya R; Roldán V; Cifuentes-Riquelme R; Crespo-Matas JA; de Los Reyes-García AM; Águila S; Fernández-Pérez MP; Reguilón-Gallego L; Zapata-Martínez L; García-Barberá N; Vicente V; Marín F; Martínez C; González-Conejero R
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33198388
[No Abstract] [Full Text] [Related]
10. Effects of Atrial Fibrillation and Chronic Kidney Disease on Major Adverse Cardiovascular Events.
Ding WY; Lip GYH; Pastori D; Shantsila A
Am J Cardiol; 2020 Oct; 132():72-78. PubMed ID: 32773222
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients.
Pastori D; Rivera-Caravaca JM; Esteve-Pastor MA; Roldán V; Marín F; Pignatelli P; Violi F; Lip GYH
Circ J; 2018 Apr; 82(5):1286-1292. PubMed ID: 29553090
[TBL] [Abstract][Full Text] [Related]
12. Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.
Huisman MV; Teutsch C; Lu S; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Lohmann R; Gurusamy VK; Bartels DB; Lip GYH;
Clin Res Cardiol; 2022 May; 111(5):548-559. PubMed ID: 35294623
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of the 2MACE score as a predictor of long-term all-cause mortality in patients with atrial fibrillation.
Szymańska A; Płatek AE; Semczuk-Kaczmarek K; Szymański FM; Dłużniewski M
Pol Arch Intern Med; 2020 Aug; 130(7-8):635-639. PubMed ID: 32539310
[TBL] [Abstract][Full Text] [Related]
14. The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study.
Pastori D; Menichelli D; Violi F; Pignatelli P; Lip GYH;
Eur J Intern Med; 2021 Mar; 85():80-85. PubMed ID: 33358066
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulant selection in relation to the SAMe-TT
Ntaios G; Huisman MV; Diener HC; Halperin JL; Teutsch C; Marler S; Gurusamy VK; Thompson M; Lip GYH; Olshansky B;
Hellenic J Cardiol; 2021; 62(2):152-157. PubMed ID: 33338644
[TBL] [Abstract][Full Text] [Related]
16. Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry.
Bayer V; Kotalczyk A; Kea B; Teutsch C; Larsen P; Button D; Huisman MV; Lip GYH; Olshansky B
J Am Heart Assoc; 2022 Mar; 11(6):e023907. PubMed ID: 35243870
[TBL] [Abstract][Full Text] [Related]
17. Impact of atrial fibrillation and the clinical outcomes in patients with acute myocardial infarction from the K-ACTIVE registry.
Mori H; Fukui K; Maeda A; Akashi Y; Ako J; Ikari Y; Ebina T; Tamura K; Namiki A; Michishita I; Kimura K; Suzuki H
J Cardiol; 2022 Jun; 79(6):768-775. PubMed ID: 35216889
[TBL] [Abstract][Full Text] [Related]
18. Correction: Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
Ding WY; Fawzy AM; Romiti GF; Proietti M; Pastori D; Huisman MV; Lip GYH; Fawzy AM;
J Thromb Thrombolysis; 2024 Jan; 57(1):178. PubMed ID: 37814089
[No Abstract] [Full Text] [Related]
19. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Lu S; Bartels DB; Lip GYH;
Am Heart J; 2018 Apr; 198():55-63. PubMed ID: 29653649
[TBL] [Abstract][Full Text] [Related]
20. Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry.
Romiti GF; Corica B; Proietti M; Mei DA; Frydenlund J; Bisson A; Boriani G; Olshansky B; Chan YH; Huisman MV; Chao TF; Lip GYH;
EClinicalMedicine; 2023 Sep; 63():102039. PubMed ID: 37753446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
